/QURE

QURE Stock - uniQure N.V.

Q: What is the analyst price target for QURE?

Analyst price target information is not currently available for QURE.

Q: What is QURE's market cap?

Market capitalization information is not currently available for QURE.

Healthcare|Biotechnology|NASDAQ

$21.50-6.68%

$1.54 (-6.68%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+116.3%upside

Target: $46.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for QURE

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.68

52W High$71.50

52W Low$7.76

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$27.12M	$15.84M	$106.48M	$524.00M	$37.51M
Gross Profit	$8.79M	$2.21M	$103.14M	$499.03M	$-84,886,000
Gross Margin	32.4%	14.0%	96.9%	95.2%	-226.3%
Operating Income	$-184,294,000	$-282,871,000	$-143,159,000	$310.62M	$-125,426,000
Net Income	$-239,556,000	$-308,478,000	$-126,789,000	$329.59M	$-125,024,000
Net Margin	-883.4%	-1947.1%	-119.1%	62.9%	-333.3%
EPS	$-4.92	$-6.47	$-2.71	$7.17	$-2.81

Company Overview

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Visit Website

Earnings History & Surprises

QURE

Beat Rate

58%

Last 19 quarters

Avg Surprise

+1.9%

EPS vs Estimate

Beats / Misses

11/8

Last 12 quarters

Latest EPS

$-1.38

Q4 2025

EPS Surprise History

Q1 24

+0.6%

$-1.53vs$-1.54

Q2 24

-3.8%

$-1.36vs$-1.31

Q3 24

+6.5%

$-1.16vs$-1.24

Q4 24

+18.8%

$-0.91vs$-1.12

Q1 25

-150.0%

$-1.50vs$-0.60

Q2 25

+23.4%

$-0.82vs$-1.07

Q3 25

+22.5%

$-0.69vs$-0.89

Q4 25

-62.4%

$-1.38vs$-0.85

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 26, 2026	$-0.93	—	—	—
Q4 2025	Nov 10, 2025	$-0.85	$-1.38	-62.4%	✗ MISS
Q3 2025	Jul 29, 2025	$-0.89	$-0.69	+22.5%	✓ BEAT
Q2 2025	May 9, 2025	$-1.07	$-0.82	+23.4%	✓ BEAT
Q1 2025	Feb 27, 2025	$-0.60	$-1.50	-150.0%	✗ MISS
Q4 2024	Nov 5, 2024	$-1.12	$-0.91	+18.8%	✓ BEAT
Q3 2024	Aug 1, 2024	$-1.24	$-1.16	+6.5%	✓ BEAT
Q2 2024	May 7, 2024	$-1.31	$-1.36	-3.8%	✗ MISS
Q1 2024	Feb 28, 2024	$-1.54	$-1.53	+0.6%	✓ BEAT
Q4 2023	Nov 7, 2023	$-1.49	$-1.88	-26.2%	✗ MISS
Q3 2023	Aug 1, 2023	$2.97	$-1.44	-148.5%	✗ MISS
Q2 2023	May 9, 2023	$-1.02	$-1.63	-59.8%	✗ MISS
Q1 2023	Feb 27, 2023	$-0.89	$0.15	+116.9%	✓ BEAT
Q4 2022	Nov 2, 2022	$-1.11	$-1.02	+8.1%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.96	$-0.84	+12.5%	✓ BEAT
Q2 2022	May 2, 2022	$-0.67	$-1.00	-49.3%	✗ MISS
Q1 2022	Feb 25, 2022	$-0.81	$0.17	+121.0%	✓ BEAT
Q4 2021	Oct 25, 2021	$-1.00	$-0.79	+21.0%	✓ BEAT
Q3 2021	Jul 26, 2021	$2.96	$8.51	+187.5%	✓ BEAT
Q2 2021	May 10, 2021	$-0.89	$-0.91	-2.2%	✗ MISS